Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
| SIGA TECHNOLOGIES INCSIGA · Entity 6205 | Director · Chief Executive Officer | March 13, 2026 | March 17, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
SIGA TECHNOLOGIES INC
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 138,767 |
Ending reported balance
After 2026-03-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-13 · Exercise / conversion · Acquired 85,045 · Balance 185,796 F1: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on March 13, 2025. Row 2 · 2026-03-13 · Tax withholding · Disposed 47,029 · Balance 138,767 F2: Represents the withholding by the Issuer of shares of Common Stock (based on $5.26 per share, the closing stock price on March 13, 2026) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 170,092 |
Reported balance
After 2026-03-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-13 · Exercise / conversion · Disposed 85,045 · Balance 170,092 F3: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 272,243 |
Reported balance
After 2026-03-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-13 · Grant · Acquired 272,243 · Balance 272,243 F3: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on March 13, 2025.
F2: Represents the withholding by the Issuer of shares of Common Stock (based on $5.26 per share, the closing stock price on March 13, 2026) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock.
F3: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant.
Verrica Pharmaceuticals Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-06-04 | Direct | 16,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,000 · Balance 16,000 F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:27 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001814338-26-000004 · ownership.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001814338-26-000002 · form4-06092026_040603.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2026 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 272,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-110759 · ownership.xml · derivative · entry 4 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,243 Underlying: Common Stock, par value $.0001 per share · 272,243 shares Expires not disclosed F3 · derivative.exercise_price: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.exercise_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.expiration_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 85,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-110759 · ownership.xml · derivative · entry 3 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,092 Underlying: Common Stock, par value $.0001 per share · 85,045 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.exercise_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.expiration_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Tax withholdingCommon Stock, par value $.0001 per share | 47,029 | $5.26 | $247,372.54 |
DisclosureSEC source: 0001193125-26-110759 · ownership.xml · nonDerivative · entry 2 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,767 F2 · shares: Represents the withholding by the Issuer of shares of Common Stock (based on $5.26 per share, the closing stock price on March 13, 2026) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 85,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-110759 · ownership.xml · nonDerivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on March 13, 2025. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 55,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-027202 · ownership.xml · derivative · entry 3 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,903 Underlying: Common Stock, par value $.0001 per share · 55,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.exercise_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.expiration_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Tax withholdingCommon Stock, par value $.0001 per share | 22,804 | $6.82 | $155,523.28 |
DisclosureSEC source: 0001193125-26-027202 · ownership.xml · nonDerivative · entry 2 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,751 F2 · shares: Represents the withholding by the Issuer of shares of Common Stock (based on $6.82 per share, the closing stock price on January 27, 2026) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:05 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 55,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-027202 · ownership.xml · nonDerivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on January 27, 2024. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:33 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087698 · ownership.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001415889-25-016288 · form4-06092025_040603.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 5, 2025 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director through the applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 21:03 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 255,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039560 · ownership.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,137 Underlying: Common Stock, par value $.0001 per share · 255,137 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F1 · derivative.exercise_date: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F1 · derivative.expiration_date: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:07 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 55,902 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010569 · ownership.xml · derivative · entry 3 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,805 Underlying: Common Stock, par value $.0001 per share · 55,902 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.exercise_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.expiration_date: RSUs represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:07 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Tax withholdingCommon Stock, par value $.0001 per share | 23,644 | $6.34 | $149,902.96 |
DisclosureSEC source: 0000950170-25-010569 · ownership.xml · nonDerivative · entry 2 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,653 F2 · shares: Represents the withholding by the Issuer of shares of Common Stock (based on $6.34 per share, the closing stock price on January 27, 2025) to satisfy tax withholding obligations associated with the vesting of RSUs and the consequent issuance of Common Stock. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:07 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 55,902 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-010569 · ownership.xml · nonDerivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the acquisition of Common Stock from the vesting of one-third of the restricted stock units ("RSUs") granted on January 27, 2024. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 21:03 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionPerformance Stock Units · Derivative | 59,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118340 · ownership.xml · derivative · entry 3 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,577 Underlying: Common Stock, par value $.0001 per share · 59,288 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: PSUs represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. On March 12, 2024, the Board of Directors of the Issuer declared a special dividend of $0.60 per share of Common Stock, and each applicable Stock Price hurdle was lowered by $0.60 accordingly. F3 · derivative.exercise_date: PSUs represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. On March 12, 2024, the Board of Directors of the Issuer declared a special dividend of $0.60 per share of Common Stock, and each applicable Stock Price hurdle was lowered by $0.60 accordingly. F3 · derivative.expiration_date: PSUs represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. On March 12, 2024, the Board of Directors of the Issuer declared a special dividend of $0.60 per share of Common Stock, and each applicable Stock Price hurdle was lowered by $0.60 accordingly. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 21:03 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Tax withholdingCommon Stock, par value $.0001 per share | 23,893 | $6.77 | $161,755.61 |
DisclosureSEC source: 0000950170-24-118340 · ownership.xml · nonDerivative · entry 2 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,395 F2 · shares: Represents the withholding by the Issuer of shares of Common Stock (based on $6.77 per share, the closing stock price on October 25, 2024) to satisfy tax withholding obligations associated with the vesting of PSUs and the consequent issuance of Common Stock. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 21:03 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 59,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118340 · ownership.xml · nonDerivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the acquisition of Common Stock from the vesting of one-third of the performance stock units ("PSUs") granted on January 27, 2024 upon achieving the $7.00 share price target (adjusted for dividends paid). Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:40 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078174 · ownership.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-24-015960 · form4-06072024_040611.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 6, 2024 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:04 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantPerformance Stock Units · Derivative | 177,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002427 · doc4.xml · derivative · entry 4 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,865 Underlying: Common Stock, par value $.0001 per share · 177,865 shares Expires not disclosed F4 · derivative.exercise_price: Performance stock units ("PSUs") represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. F4 · derivative.exercise_date: Performance stock units ("PSUs") represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. F4 · derivative.expiration_date: Performance stock units ("PSUs") represent contingent rights to receive Common Stock on a one-for-one basis. These PSUs vest as follows: (a) one-third of these PSUs vest if, during any period of 90 consecutive trading days during the three-year period beginning on the grant date (the "Performance Period"), the Issuer's Common Stock closing stock price (plus the per share value of any dividends issued during the measurement date) (the "Stock Price") is at or above $7.00, (b) one-third of these PSUs vest, if during any period of 90 consecutive trading days during the Performance Period, the Stock Price is at or above $8.00, and (c) one-third of these PSUs vest, if during any 90 consecutive trading days during the Performance Period, the Stock Price is at or above $9.00. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:04 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 167,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002427 · doc4.xml · derivative · entry 3 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,707 Underlying: Common Stock, par value $.0001 per share · 167,707 shares Expires not disclosed F3 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.exercise_date: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. F3 · derivative.expiration_date: Restricted stock units ("RSUs") represent contingent rights to receive Common Stock on a one-for-one basis. The RSUs vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:04 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantStock Option (Right to buy) · Derivative | 219,212 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-24-002427 · doc4.xml · derivative · entry 2 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,212 Underlying: Common Stock, par value $.0001 per share · 219,212 shares Expires 2034-01-27 F2 · derivative.exercise_date: The options vest over three years, one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| January 27, 2024 Filed Jan 30, 2024 22:04 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantStock Option (Right to buy) · Derivative | 109,606 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-24-002427 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,606 Underlying: Common Stock, par value $.0001 per share · 109,606 shares Expires 2034-01-27 F1 · derivative.exercise_date: The options vest over two years, one-half on each of the first two anniversaries of the date of grant. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 13:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-040135 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 13:03 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-23-036147 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:45 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-053830 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2032-10-13 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) October 13, 2023 or (ii) the date of the next Annual Meeting of Stockholders of the Company; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Company or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:16 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 10,384 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-22-036293 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,384 Underlying: Common Stock · 10,384 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:11 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 10,000 | $8.00 | $80,000.00 |
DisclosureSEC source: 0000899243-21-031102 · doc4.xml · nonDerivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 26, 2021 Filed Feb 14, 2022 21:43 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,840 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006188 · doc5.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,840 Underlying: Common Stock · 28,840 shares Expires 2031-07-26 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six equal monthly installments following July 26, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 26, 2021 Filed Feb 15, 2022 01:31 UTC Amendment | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,480 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006325 · doc5a.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2031-07-26 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six equal monthly installments following July 26, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:55 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 5,834 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-040264 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 5,834 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 17, 2021 20:35 UTC Amendment | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 8,109 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041447 · doc4a.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Underlying: Common Stock · 8,109 shares Expires 2031-06-09 F1 · shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 10, 2021 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. F1 · balance_after: The original Form 4 filed on June 14, 2021 inadvertently listed the incorrect number of options granted to the Reporting Person. This amendment is being file to accurately reflect the true number of options granted. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:11 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantStock Option (right to buy) · Derivative | 17,502 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001209191-20-035997 · doc4.xml · derivative · entry 1 Nguyen Diem · CIK 0001814338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,502 Underlying: Common Stock · 17,502 shares Expires 2030-06-08 F1 · derivative.exercise_date: 1/3rd of the total shares subject to the option shall vest on June 9, 2021 and 1/36th of the total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.